Dividend, Financial Results, Publishing of Clinical Study Data, New Offerings and Conference Call Schedules - Analyst Notes on H&R Block, Ulta Beauty, Myriad, QIAGEN, and Nutrisystem

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Mar 12, 2014, 08:00 ET

NEW YORK, March 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding H&R Block Inc. (NYSE: HRB), Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ: ULTA), Myriad Genetics, Inc. (NASDAQ: MYGN), QIAGEN NV (NASDAQ: QGEN), and Nutrisystem Inc. (NASDAQ: NTRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

H&R Block Inc. Analyst Notes

On March 5, 2014, H&R Block Inc. (H&R Block) announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share. According to the Company, shareholders of record as of March 17, 2014 can collect payments on April 1, 2014, which would also mark H&R Block's 206^th consecutive quarterly dividend since it went public in 1962. The full analyst notes on H&R Block Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/HRB/report.pdf

Ulta Salon, Cosmetics & Fragrance, Inc. Analyst Notes

On March 3, 2014, Ulta Salon, Cosmetics & Fragrance, Inc. (Ulta Beauty) reported that it has scheduled a conference call to discuss its upcoming Q4 2013 and full-year 2013 financial results on Thursday, March 13, 2014 at 5:00 p.m. ET/4:00 p.m. CT. The Company informed that Mary Dillon, CEO, and Scott Settersten, CFO of the Company will host the call. Ulta Beauty stated that a press release with details of its Q4 2013 and full-year 2013 results will also be issued on the aforesaid date after the market closes and prior to the call. The full analyst notes on Ulta Salon, Cosmetics & Fragrance, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/ULTA/report.pdf

Myriad Genetics, Inc. Analyst Notes

On March 3, 2014, Myriad Genetics, Inc. (Myriad) announced that data from its PROCEDE 500 study - a prospective registry study that was designed to evaluate the impact of the Prolaris test on physician treatment recommendations for patients with prostate cancer, was published in the journal Current Medical Research and Opinion. According to Myriad, the data showed that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients. "Prolaris is an absolute game changer for urologists because it adds meaningful new prognostic information in terms of risk assessment for prostate cancer patients that will improve their care," said E. David Crawford, M.D., Head of the Section of Urologic Oncology at the University of Colorado. "In this study, Prolaris led to major changes in therapies with significant reductions or increases in interventional treatments that were based on patients' unique risk profiles." The full analyst notes on Myriad Genetics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/MYGN/report.pdf

QIAGEN NV Analyst Notes

On February 26, 2014, QIAGEN NV (QIAGEN) announced the commercial launch of careHPV^[^TM^] Test in India. According to QIAGEN, the careHPV^[^TM^] Test is the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with limited healthcare infrastructure, such as areas lacking electricity, water or laboratories. "The launch of careHPV in India will help in efforts to reduce the high burden of cervical cancer for women in India," said Dr. Victor Shi, President of QIAGEN Asia Pacific. "With the digene HC2 HPV Test serving areas that have modern healthcare infrastructure and the careHPV Test serving low-resource areas, QIAGEN is expanding our role as the global leader in preventive screening for cervical cancer and continuing to contribute to women's health around the world." The full analyst notes on QIAGEN NV are available to download free of charge at:

http://www.AnalystsReview.com/03122014/QGEN/report.pdf

Nutrisystem Inc. Analyst Notes

On February 26, 2014, Nutrisystem Inc. (Nutrisystem) announced its Q4 2013 and full-year 2013 financial results. The Company posted revenues of $69.9 million in Q4 2013, up 11.8% YoY, while full-year 2013 revenues dropped 9.8% YoY to $358.1 million. Q4 2013 GAAP net income was $1.3 million as compared to a net loss of $5.0 million in Q4 2012. Full-year 2013 net income was $7.3 million or $0.25 per diluted share, against a net loss of $2.8 million or loss per diluted share of $0.10. Commenting on the results, Nutrisystem's CFO, Mike Monahan, remarked, "We had a number of improvements on a year-over-year basis. We achieved revenue growth in the second half of 2013 by executing on new customer acquisition plans we put in place at the beginning of the year. We successfully improved adjusted EBITDA and adjusted net income in both the fourth quarter of 2013 and over the full year. We also grew free cash flow during 2013, enabling us to fund initiatives to drive future growth." Monahan added, "We are projecting revenues of $116 million to $121 million for the first quarter of 2014 and $385 million to $405 million for full year 2014. Earnings per share for the first quarter of 2014 are expected to be in the range of ($0.07) to ($0.02), and in the range of $0.51 to $0.61 for full year 2014." The full analyst notes on Nutrisystem Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/NTRI/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review